Tag: Avinger

Avinger Receives CE Marking Approval for Pantheris SV, a New Image-Guided Atherectomy Device Designed to Treat Smaller Vessels

REDWOOD CITY, CA / ACCESSWIRE / October 18, 2018 / Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced Conformité Européenne (CE) Marking approval of Pantheris SV (Small Vessel), a product line extension of the Lumivascular atherectomy system. CE Marking allows for distribution […]

Avinger Announces 510(k) Filing of Pantheris Small Vessel Device

REDWOOD CITY, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) — Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the Company submitted a new 510(k) application to the U.S Food & Drug Administration (FDA) for the Pantheris SV (Small Vessel) Lumivascular atherectomy system. Pantheris […]

Avinger Announces Participation in Upcoming Investor Conferences

REDWOOD CITY, Calif., Aug. 28, 2018 (GLOBE NEWSWIRE) — Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that management of Avinger will present at the following investor conferences: Rodman & Renshaw 20th Annual Global Investment Conference, sponsored by H.C. Wainwright & […]

Avinger Announces Pricing of $3.55 Million Registered Direct Offering

REDWOOD CITY, Calif., July 12, 2018 (GLOBE NEWSWIRE) — Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 2,166,180 shares of common stock […]

Avinger Appoints Jaafer Golzar, MD, FACC, FSCAI, as Chief Medical Officer

REDWOOD CITY, Calif., July 10, 2018 (GLOBE NEWSWIRE) — Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the appointment, effective immediately, of Jaafer Golzar, MD, as the Company’s Chief Medical Officer. Dr. Golzar provides Avinger with an extensive and impressive history of […]

Avinger Announces Successful Treatment of First Patients with Next-Generation Pantheris in Several Centers throughout the US

REDWOOD CITY, Calif., June 26, 2018 (GLOBE NEWSWIRE) — Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that several physicians have successfully treated over 40 patients in the US across 13 sites with the next-generation Pantheris image-guided atherectomy system for the treatment […]

Avinger’s Ocelot Technology Featured in Live Case Transmission at Complex Cardiovascular Catheter Therapeutics (C3) 2018

REDWOOD CITY, Calif., June 21, 2018 (GLOBE NEWSWIRE) — Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that its Ocelot image-guided chronic total occlusion (CTO) crossing device was featured in a live case on June 19th at Complex Cardiovascular Catheter Therapeutics (C3) 2018 […]

Avinger Announces First Patients Enrolled in Post-Market Study Comparing Pantheris OCT Imaging to Intravascular Ultrasound

REDWOOD CITY, Calif., June 14, 2018 (GLOBE NEWSWIRE) — Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the initiation of the SCAN study, a post-market study comparing optical coherence tomography (OCT) with intravascular ultrasound (IVUS) as a diagnostic imaging tool in the […]